Japan suspends imports of fertile eggs, day-old chicks from two Brazilian states
SAO PAULO (Reuters) -Japan suspended imports of fertile eggs and day-old chicks coming from the Brazilian states of Goias and Mato Grosso after bird flu cases in subsistence farms had been reported in both states, the Brazilian Agriculture Ministry said on Tuesday.
In a statement, the ministry added that Japan also suspended all poultry meat imports from the cities where the cases were reported, Santo Antonio da Barra in Goias and Campinapolis in Mato Grosso.
(Reporting by Andre Romani; Editing by Kylie Madry)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
a day ago
- The Star
Exclusive-US to drop guidance to limit alcohol to one or two drinks per day, sources say
(Reuters) -U.S. Dietary Guidelines are expected to eliminate the long-standing recommendation that adults limit alcohol consumption to one or two drinks per day, according to three sources familiar with the matter, in what could be a major win for an industry threatened by heightened scrutiny of alcohol's health effects. The updated Dietary Guidelines for Americans, which could be released as early as this month, are expected to include a brief statement encouraging Americans to drink in moderation or limit alcohol intake due to associated health risks, the sources said. The guidelines are still under development and subject to change, two of the sources and a fourth individual familiar with the process said. Currently, the recommendations advise limiting drinking to one serving or less per day for women and two or less for men, widely seen as a moderate level. Similar guidelines exist in countries such as the United Kingdom, which advises limiting drinking to 14 units per week, while Canada, however, has adopted a more cautious stance, warning that health risks begin to increase after just two drinks per week. Even moderate drinking is linked to some health risks, such as higher risk of breast cancer, though some studies have also found an association with possible health benefits, such as a lower risk of stroke. The fourth source said that the scientific basis for recommending specific daily limits is limited, and the goal is to ensure the guidelines reflect only the most robust evidence. The new guidelines, developed by the U.S. Department of Health and Human Services and the U.S. Department of Agriculture, are closely watched internationally and influence policies ranging from school lunch programs to medical advice. Neither department responded to requests for comment. Health Secretary Robert F. Kennedy Jr., a known teetotaler, has remained largely silent on alcohol but has emphasised a focus on whole foods in the upcoming guidelines. Some alcohol executives had feared a move towards tighter recommendations on alcohol intake as authorities like the World Health Organization upped their warnings about alcohol's health risks. Former U.S. Surgeon General Vivek Murthy said alcohol consumption increases the risk of at least seven types of cancer and called for warning labels on alcoholic drinks. Major industry players, including Diageo and Anheuser-Busch InBev, have lobbied lawmakers throughout the review process. Senate records show each company spent millions on lobbying efforts related to the guidelines and a range of other issues such as tax and trade in 2024 and 2025. Both companies declined to comment. The new guidelines are set to move away from suggesting consumers limit alcohol consumption to a specific number of daily servings, according to the three sources, who asked not to be named in order to speak freely. One person said the new alcohol-related recommendation will probably be limited to a sentence or two. Another said the existing numbers tied to moderate drinking could still appear in a longer appendix. While industry representatives have lobbied lawmakers on the guidelines or how they should be decided, some officials and researchers advocated for tighter restrictions. Reports intended to inform the guidelines have meanwhile drawn different conclusions about alcohol's health effects and the science around this. 'UNHELPFUL' The guidelines, which are reviewed every five years, have advised drinking in moderation and defined that as no more than one drink per day for women and no more than two for men since 1990. Eva Greenthal, a senior policy scientist at the Center for Science in the Public Interest, a non-profit focused on nutrition, health and food safety, said the more general language expected in the guidelines was "so vague as to be unhelpful". Under such a change, the message that even moderate drinking can increase risks, especially for breast cancer, would get lost, she continued. Two studies were produced to inform the development of the guidelines. The first found that moderate drinking was associated with increased risk of some cancers, but a decreased risk of dying from any cause and some cardiovascular problems like stroke. The evidence for some other health impacts was insufficient to draw conclusions, it found. The other report conversely found the risk of dying from alcohol use, including increased risk for seven cancers, begins at any or low levels of alcohol use and increases with higher consumption. (Reporting by Emma Rumney in London and Jessica Di'Napoli in New York; editing by Caroline Humer and Louise Heavens)
The Star
2 days ago
- The Star
Japan suspends imports of fertile eggs, day-old chicks from two Brazilian states
SAO PAULO (Reuters) -Japan suspended imports of fertile eggs and day-old chicks coming from the Brazilian states of Goias and Mato Grosso after bird flu cases in subsistence farms had been reported in both states, the Brazilian Agriculture Ministry said on Tuesday. In a statement, the ministry added that Japan also suspended all poultry meat imports from the cities where the cases were reported, Santo Antonio da Barra in Goias and Campinapolis in Mato Grosso. (Reporting by Andre Romani; Editing by Kylie Madry)
The Sun
3 days ago
- The Sun
U.S. drugmakers boost licensing deals with Chinese biotechs
U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments. Through June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to Reuters. That increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters. "They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig Suvannavejh. The total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData. A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development risks. China's share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in March. Chinese companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and development. While small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. "Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony Ren. The growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America agenda. That has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from database. Roughly a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%. "I think it's only accelerating," Gleason said. The Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical sector. But one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs. "The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare group. In May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio . That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is successful. Regeneron Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals. 'WAKEUP CALL' By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say. U.S.-based drug developer Nuvation Bio bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week. "We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told Reuters. What makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time." Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry. "It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
